Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Varespladib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A known ✓ | P14555 | 17/20 | 0.83 |
| ▸ | PLA2G10 | O15496 | 7/20 | 0.83 |
| ▸ | PLA2G1B | P04054 | 6/20 | 0.83 |
| ▸ | PLA2G2E | Q9NZK7 | 6/20 | 0.83 |
| ▸ | PLA2G2D | Q9UNK4 | 5/20 | 0.83 |
| ▸ | PLA2G5 | P39877 | 5/20 | 0.83 |
| ▸ | PLA2G2F | Q9BZM2 | 4/20 | 0.83 |
| ▸ | PLA2G6 | O60733 | 1/20 | 0.83 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.83 |
| ▸ | PLA2G12B | Q9BX93 | 1/20 | 0.83 |
| ▸ | PLA2G12A | Q9BZM1 | 1/20 | 0.83 |
| ▸ | PLA2G3 | Q9NZ20 | 1/20 | 0.83 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Varespladib SCHEMBL29430154 | 1.00 | PLA2G2A (0.83) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G2D | |
| Varespladib SCHEMBL29358982 | 0.91 | PLA2G2A (1.00) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G2D | |
| Varespladib SCHEMBL26726 | 0.91 | PLA2G2A (1.00) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G2D | |
| Varespladib Methyl SCHEMBL29378302 | 0.88 | PLA2G2A (0.83) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G2D | |
| Varespladib Methyl SCHEMBL25678 | 0.88 | PLA2G2A (0.83) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G2D | |
| SCHEMBL6694837 | 0.88 | PLA2G2A (0.83) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G2D | |
| SCHEMBL8374858 | 0.88 | PLA2G2A (0.84) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G2D | |
| SCHEMBL5710708 | 0.87 | PLA2G2A (0.82) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G2D | |
| SCHEMBL5710700 | 0.87 | PLA2G2A (0.82) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G2D | |
| SCHEMBL6812616 | 0.87 | PLA2G2A (0.82) | PLA2G2APLA2G10PLA2G1BPLA2G2EPLA2G2D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1058547-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING THE PHOSPHOLIPASE INHIBITOR SODIUM 3-(2-AMINO-1,2-DIOXOETHYL)-2-ETHYL-1-PHENYLMETHYL)-1H-INDOL-4-YL]OXY]ACETATE | SHIONOGI & CO (JP) | 2005-11-23 | — | — | EP | claimed |
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | MODEL MEDICINES, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-4667008-A2 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | Model Medicines, Inc. (US) | 2025-12-24 | — | — | EP | disclosed |
| US-20230248712-A1 | METHODS AND COMPOSITIONS FOR TREATING RNA VIRAL INFECTIONS | MODEL MEDICINES, INC. | 2023-08-10 | — | — | US | disclosed |
| EP-2029134-B1 | STABILIZED PHARMACEUTICAL COMPOSITIONS COMPRISING FESOTERODINE | UCB PHARMA GMBH (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| JP-2011021042-A | PHARMACEUTICAL COMPOSITION CONTAINING PHOSPHOLIPASE INHIBITOR SODIUM [[3-(2-AMINO-1,2-DIOXOETHYL)-2-ETHYL-1-(PHENYLMETHYL)-1H-INDOL-4-YL]OXY]ACETATE | ANTHERA PHARMACEUTICALS INC | 2011-02-03 | — | — | JP | disclosed |
| JP-2011021042-A | PHARMACEUTICAL COMPOSITION CONTAINING PHOSPHOLIPASE INHIBITOR SODIUM [[3-(2-AMINO-1,2-DIOXOETHYL)-2-ETHYL-1-(PHENYLMETHYL)-1H-INDOL-4-YL]OXY]ACETATE | ANTHERA PHARMACEUTICALS INC | 2011-02-03 | — | — | JP | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1303262-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002005796-A2 | USE OF A SPLA2 INHIBITOR FOR THE TREATMENT OF SEPSIS | ELI LILLY AND COMPANY (US) | 2002-01-24 | — | — | WO | disclosed |
| WO-2001044182-A2 | NEW SYNTHESIS OF SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001044185-A1 | CARBON MONOXIDE-BASED SYNTHESIS OF SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
| WO-2001044184-A1 | SYNTHESIS OF INDOLE-CONTAINING SPLA2 INHIBITORS | ELI LILLY AND COMPANY (US) | 2001-06-21 | — | — | WO | disclosed |
| US-5986106-A | Process for preparing 4-substituted-1H-indole-3-glyoxamides | ELI LILLY AND COMPANY (US) | 1999-11-16 | — | — | US | disclosed |
| EP-0887342-A2 | Process for preparing 4-substituted-1H-indole-3-glyoxamides | ELI LILLY AND COMPANY (US) | 1998-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12551475-B2 | Methods and compositions for treating RNA viral infections | SARS1, EIF2AK2, SNRPE | PLA2G2A 1645/4885PLA2G10 1976/4885PLA2G1B 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.